TY - JOUR
T1 - Rapid virological response obtained by natural IFN α for a patient of chronic hepatitis C with a high viral load of HCV genotype 1b who is refractory to peg-interferon α+ ribavirin combination therapy
AU - Kawano, Akira
AU - Kado, Yuichiro
AU - Shigematsu, Hirohisa
AU - Miki, Koichiro
AU - Maruyama, Toshihiro
AU - Nomura, Hideyuki
AU - Shimoda, Shinji
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - Interferon monotherapy is considered to have limited effectiveness in patients with HCV of a high viral load. Here, we reported a 21-year old male of chronic hepatitis C with a high viral load of HCV genotype 1b. He received both peg-interferon α-2b plus ribavirin and peg-interferon α-2a plus ribavirin combination therapy. But there were no virological response Nevertheless, after starting natural interferon α (human lymphoblastoid interferon (HLBI), Sumiferon; Dainippon Sumitomo Pharmaceutical Co., Osaka, Japan), he became HCV-RNA negative at 4 week. The therapy is continued and HCV-RNA negativity is sustained for over 40 weeks. Eradication of HCV might be expected. Natural IFN α contains more than 20 subtypes, and one or more of them may have therapeutic effect against HCV virus of this patient.
AB - Interferon monotherapy is considered to have limited effectiveness in patients with HCV of a high viral load. Here, we reported a 21-year old male of chronic hepatitis C with a high viral load of HCV genotype 1b. He received both peg-interferon α-2b plus ribavirin and peg-interferon α-2a plus ribavirin combination therapy. But there were no virological response Nevertheless, after starting natural interferon α (human lymphoblastoid interferon (HLBI), Sumiferon; Dainippon Sumitomo Pharmaceutical Co., Osaka, Japan), he became HCV-RNA negative at 4 week. The therapy is continued and HCV-RNA negativity is sustained for over 40 weeks. Eradication of HCV might be expected. Natural IFN α contains more than 20 subtypes, and one or more of them may have therapeutic effect against HCV virus of this patient.
UR - http://www.scopus.com/inward/record.url?scp=73849105335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73849105335&partnerID=8YFLogxK
U2 - 10.2957/kanzo.50.590
DO - 10.2957/kanzo.50.590
M3 - Article
AN - SCOPUS:73849105335
VL - 50
SP - 590
EP - 592
JO - Acta Hepatologica Japonica
JF - Acta Hepatologica Japonica
SN - 0451-4203
IS - 10
ER -